January 20 th, 2011 – Stempeutics Research a group company of Manipal Education & Medical Group announced that Drug Controller General of India (DCGI) has granted clearance of the company’s Investigational Medicinal Product “Stempeucel” for conducting Phase II clinical trials in patients with Osteo Arthritis, Diabetes Mellitus – Type2, Liver Cirrhosis and Chronic Obstructive Pulmonary Disease. Stempeucel product is developed from allogeneic mesenchymal stem cells derived from donated bone marrow using Stempeutics proprietary technology. Earlier the company has received approval from DCGI for Phase I/II clinical trial for Acute Myocardial Infarction and Critical Limb Ischemia in March 2009. Stempeutics is funded by Manipal Group and Cipla...
[...]
...Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a disease of the lungs in which the airways become narrowed. This leads to a restriction to the flow of air to and from the lungs causing shortness of breath. Currently the available treatment options are targeted at only symptomatic relief of COPD, which do not provide long term benefits to the patients. Mesenchymal stem cells are thought to stimulate the endogenous stem cells and help them to differentiate into alveolar epithelium, thus repairing the lung damage and improving pulmonary function. This study involves the evaluation of safety and efficacy of “Stempeucel” in COPD and finding the appropriate safe and effective dose for the disease... [PDF] Stempeutics Research's Press Release -
